A Survey of Lanadelumab in Participants With Hereditary Angioedema

Status Recruiting

Clinical Trial Summary

This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05397431
Study type	Observational
Source	Takeda
Contact	Takeda Contact
Phone	+1-877-825-3327
Email	medinfoUS@takeda.com
Status	Recruiting
Phase
Start date	May 30, 2022
Completion date	August 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02865720` - Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)	Phase 3
Completed	`NCT04861090` - A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
Recruiting	`NCT05489640` - A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home
Completed	`NCT02584959` - Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema	Phase 3
Completed	`NCT01826916` - EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema	Phase 2
Completed	`NCT04057131` - FIRAZYR General Drug Use-Results Survey (Japan)
Recruiting	`NCT05819775` - CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema	Phase 3
Completed	`NCT02741596` - Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE	Phase 3
Completed	`NCT02093923` - A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants	Phase 1
Completed	`NCT01541423` - A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
Completed	`NCT03845400` - A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America
Completed	`NCT02586805` - Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE	Phase 3
Completed	`NCT02052141` - Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema	Phase 3
Completed	`NCT03888755` - A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants	Phase 3
Recruiting	`NCT05147181` - A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
Recruiting	`NCT05469789` - A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
Completed	`NCT05460325` - A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)	Phase 3
Completed	`NCT01095510` - CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12	Phase 2
Recruiting	`NCT05578417` - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
Withdrawn	`NCT01253382` - Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema	Phase 2/Phase 3